# Velocimed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/velocimed

- Industry: Healthcare
- Headquarters: Maple Grove, US
- Website: www.velocimed.com
- Total disclosed funding: $16M
- Latest round: Series D (Sep 21, 2004)
- Investors on record: 4

## About

Based in Maple Grove, Minnesota, Velocimed is a private company focused on the development of three novel cardiovascular devices: (i) Proxis, the company’s lead product, designed to reduce the incidence of adverse outcomes due to the release of thrombotic emboli during high-risk coronary stenting procedures and representing the first proximal approach to coronary embolic protection; (ii) the Premere PFO Closure System, a patent foramen ovale (PFO) percutaneous closure device designed to seal a small channel in the septum of the heart between the atria, a common congenital defect associated with cryptogenic stroke; and (iii) the Venture Wire Control Catheter, a device designed to provide fine steering control and focused pushability to direct a standard guide wire through tight lesions.

## Funding rounds

- Series D, Sep 21, 2004, $16M — Warburg Pincus, RiverVest Ventures Partners, Vertical Group, Arnerich Massena & Associates

## Investors

- Warburg Pincus (https://capitalatlas.ai/funds/warburg-pincus) — Series D
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series D
- Vertical Group (https://capitalatlas.ai/funds/vertical-group) — Series D
- Arnerich Massena & Associates — Series D